Europe Prothrombin Complex Concentrate Market to Grow at 10.9% CAGR and to Hit USD 398.9 Million till 2027

 

Pune, India, April 05, 2021 (GLOBE NEWSWIRE) — The Europe prothrombin complex concentrate market size is projected to reach USD 398.9 million by 2027, exhibiting a CAGR of 10.9% during the forecast period. The substantial advantages offered by prothrombin complex concentrate (PCC) will be the primary driving force behind this market’s growth, forecasts Fortune Business Insights™ in its report, titled “Europe Prothrombin Complex Concentrate Market Size, Share & Covid-19 Impact Analysis, By Product (4-factor PCC and 3-factor PCC), By Application (Acquired Coagulation Deficiency and Congenital Coagulation Deficiency and By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, and Others), 2020-2027”.

PCC (factor IX complex) is a medication comprising blood clotting factors II, IX, and X, indicated for treating bleeding in patients with hemophilia B. This line of treatment offers a host of benefits, especially when compared to Fresh Frozen Plasma (FFP), a leading anticoagulation-reversal therapy.

Industry Development:

  • August 2019: Octapharma AG announced the launch of its 4-factor prothrombin complex concentrate, Pronativ, indicated to arrest and reverse surgical blood loss.

 

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/europe-prothrombin-complex-concentrate-pcc-market-104721

 

Increasing Geriatric Populations across Europe to Create Market Opportunities

An emerging factor driving the Europe prothrombin complex concentrate market growth is the rapidly aging populations across the continent. According to the latest data released by the UN’s Population Division, nearly 25% of Europe’s people are aged 60 years and above. Moreover, the European Commission (EC) predicts that the proportion of people above the age of 80 in the EU-27 will increase from 5.8% to 14.6% between 2019 and 2100. Older persons are at a heightened risk of acute liver injury and also face increased susceptibility to the fibrotic response. Prothrombin complex concentrate has proven to be highly effective in treating patients with liver disease as they frequently develop coagulopathy.

A study conducted in 2019 by researchers from the Royal Free Hospital, London and University College London found that PCC therapy was effective in improving coagulation test results in patients with liver disease, without any excess thrombotic events. Such research studies proving the efficacy of PCC treatments, complemented by a rising number of older persons, will bolster the prospects of this market in Europe.

 

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/europe-prothrombin-complex-concentrate-pcc-market-104721

 

Germany to Spearhead the Europe PCC Market; the UK to Display Promising Growth

Germany is anticipated to headline the Europe prothrombin complex concentrate market share during the forecast period owing to a large pool of patients suffering from congenital factor IX deficiency. In 2019, the country’s market size stood at USD 46.0 million. In the UK, on the other hand, the rising incidence of hemophilia B will be the principal growth driver for the country’s market. Further, the market in Scandinavia will be propelled by the strong presence and operations of CSL Behring in the region and the wide popularity of its prothrombin complex concentrate brand, Confidex.

The COVID-19 pandemic eruption has wreaked unprecedented havoc across nations, brought the world economy to a grinding halt, and has given rise to widespread uncertainty, anxiety, and panic across industries. Governments are taking the necessary steps to pull their countries out of this crisis, while private companies are exploring alternative strategies to survive these hard times. At Fortune Business Insights™, we are striving to gain market intelligence to equip you with updated information and aid your efforts at wading through this crisis. We are offering precise market reports based on our expertise and experience in the field of market research.

 

Quick Buy Europe Prothrombin Complex Concentrate Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/104721

 

List of Key Companies Profiled in the Europe Prothrombin Complex Concentrate Market Report:

  • Takeda Pharmaceutical Company Limited (Tokyo, Japan)
  • Kedrion S.p.A (Lucca, Italy)
  • Grifols, S.A. (Barcelona, Spain)
  • Sanquin (Amsterdam, The Netherlands)
  • Octapharma AG (Lachen, Switzerland)
  • CSL Limited (Melbourne, Australia)

New Product Introductions to Charge up Market Competition

The competitive dynamics of the Europe prothrombin complex concentrate market are dictated by the presence of a limited number of key players, mainly pharmaceutical giants in Europe. These companies are concentrating on releasing new PCC products to capture the growing regional demand for efficient solutions to manage bleeding disorders.

 

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/europe-prothrombin-complex-concentrate-pcc-market-104721

 

Table of Content :

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Epidemiology of Coagulation Factor Deficiency – For Key Countries
    • Recent Industry Developments – Partnerships, Mergers & Acquisitions
    • Regulatory Scenario – For Key Countries
    • Analysis in Relation to Alternatives to PCC
    • PCC Market: Reimbursement Scenario & Key Industry Trends
    • Impact of COVID-19 on Europe PCC Market
  • Europe Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Product – By Value (US$, Mn)
      • 3-factor PCC
      • 4-factor PCC
    • Market Analysis, Insights and Forecast – By Application-By Value (US$, Mn)
      • Acquired Coagulation Factor Deficiency
      • Congenital Coagulation Factor Deficiency
    • Market Analysis, Insights and Forecast – By End User – By Value (US$, Mn)
      • Hospitals
      • Ambulatory Surgical Centers
      • Others
    • Market Analysis, Insights and Forecast – By Country/Sub-region
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
      • Scandinavia
      • Rest of Europe
  • U.K. Prothrombin Complex Concentrate Market Analysis, Insights and Forecast, 2016-2027
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Product – By Value (US$, Mn)
      • 3-factor PCC
      • 4-factor PCC
    • Market Analysis, Insights and Forecast – By Application-By Value (US$, Mn)
      • Acquired Coagulation Factor Deficiency
      • Congenital Coagulation Factor Deficiency
    • Market Analysis, Insights and Forecast – By End User – By Value (US$, Mn)
      • Hospitals
      • Ambulatory Surgical Centers
      • Others

TOC Continued….!

 

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/europe-prothrombin-complex-concentrate-pcc-market-104721

 

Have a Look at Related Reports:

ePharmacy Market Size, Share and Global Trend By Product (Over-the-Counter Products, Prescription Medicine) and Geography forecast till 2026

Microfluidic Devices Market Size, Share & Industry Analysis, By Device Type (Chips, Sensors, and Others), By Material (Glass, Silicon, Polymer and Others), By Applications (Pharmaceutical & Life Science Research, Diagnosis & Treatment, and Others), By End-user (Diagnostic Centers, Research Institutes, Pharmaceutical and Biotechnology Companies, Healthcare Facilities and Others) and Regional Forecast, 2019-2026

Orthopedic Implants Market Size , Share & Industry Analysis, By Product (Joint Reconstruction; Spinal Implants; Trauma Implants, Dental Implants; Orthobiologics, and Others) End-user (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, and Others) and Regional Forecast, 2019-2026

Anticoagulants Market Size, Share & Industry Analysis, By Disease Indication (Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Atrial Fibrillation, Heart Attacks, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026

 

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

 

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: [email protected] m
Fortune Business Insights™
LinkedIn | Twitter | Blogs

 

Press Release: https://www.fortunebusinessinsights.com/press-release/europe-prothrombin-complex-concentrate-pcc-market-10507


Primary Logo